Reykjavik:MYCR.ST

Mycronic receives order for an FPS 6100 Evo

STOCKHOLM, July 13, 2021 /PRNewswire/ -- Mycronic AB (publ) has received an order for an FPS 6100 Evo from an existing customer inAsia. The order value is in the range ofUSD 3-5 million and delivery of the system is planned for the fourth quarter of 2021. FPS 6100 Evo is a mask writer for the mu...

2021-07-13 19:57 1269

Week's Top Stories

Most Reposted

Multiple achievements made in China-Hungary BRI conference

[Picked up by 319 media titles]

2024-05-03 06:59
Multiple achievements made in China-Hungary BRI conference

VentureBlick Launches 'Discovery': The First Global Networking Platform for Healthcare Innovation

[Picked up by 319 media titles]

2024-05-08 14:37
VentureBlick Launches 'Discovery': The First Global Networking Platform for Healthcare Innovation

Shanghai Jiao Tong University Offers Free Online Courses for International Learners, Joint Programs with Tmall of Alibaba and Dow Gain High Popularity

[Picked up by 318 media titles]

2024-05-07 08:00
Shanghai Jiao Tong University Offers Free Online Courses for International Learners, Joint Programs with Tmall of Alibaba and Dow Gain High Popularity

OPTIX raises US$15 million fundraising to date to solve the bottleneck of XR optics technology

[Picked up by 310 media titles]

2024-05-08 08:00

IN2MF in Kuala Lumpur Presented by Bank Indonesia

[Picked up by 296 media titles]

2024-05-08 16:44
IN2MF in Kuala Lumpur Presented by Bank Indonesia

Most Read

/C O R R E C T I O N -- Addverb/

2024-05-03 20:26 15061
/C O R R E C T I O N -- Addverb/

Multiple achievements made in China-Hungary BRI conference

2024-05-03 06:59 10501
Multiple achievements made in China-Hungary BRI conference

Xinhua president, Hungarian economy minister vow to bolster media cooperation

2024-05-03 06:25 9876

Hang Seng Insurance Introduces FortuneLife Deferred Annuity Life Insurance Plan with Enhanced Benefit to Support Stable Retirement

2024-05-03 14:47 6633
Hang Seng Insurance Introduces FortuneLife Deferred Annuity Life Insurance Plan with Enhanced Benefit to Support Stable Retirement

Minghui Pharmaceutical to Present the Phase I/II Study of MHB088C (B7-H3 ADC) for the Treatment of Patients with Recurrent or Metastatic Solid Tumors in Late-breaking Oral Presentation at the 2024 ASCO Annual Meeting

2024-05-08 18:18 5214